PTI stock forecast
Our latest prediction for Proteostasis Therapeutics, Inc.'s stock price was made on the Dec. 18, 2017 when the stock price was at 4.47$.
In the short term (2weeks), PTI's stock price should outperform the market by 5.31%. During that period the price should oscillate between -12.40% and +31.04%.
In the medium term (3months), PTI's stock price should outperform the market by 6.95%. During that period the price should oscillate between -22.52% and +73.28%.Get email alerts
About Proteostasis Therapeutics, Inc.
Proteostasis Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It engages in the discovery and development of novel therapeutics to treat cystic fibrosis (CF) and other diseases caused by an imbalance in the proteostasis network. The company was founded by William Balch, Jeffery W. Kelly, Andrew Dillin, Richard I. Morimoto, Alfred Lewis Goldberg, Daniel Finley, Christopher T. Walsh, and Randall W. King in 2006 and is headquartered in Boston, MA.
At the moment the company generates 5M USD in revenues.
On its last earning announcement, the company reported a loss of -1.28$ per share.
The book value per share is 1.54$
Three months stock forecastDec. 18, 2017
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|